67 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 MABION Novavax, a leading innovator in vaccine development, sought a trusted, and highly capable CDMO partner to support the production of its recombinant protein-based vaccine. Mabion emerged as the ideal partner, bringing its deep expertise in biologics manufacturing, advanced infrastructure, and regulatory compliance to the forefront. This partnership validates our capabilities in advanced biologics manufacturing, demonstrating our ability to meet the highest regulatory standards, including compliance with FDA cGMP requirements. Mabion has proven its ability to rapidly adopt and optimize complex biologics manufacturing processes. With its proven track record, Mabion is actively seeking new U.S. biopharma collaborations in monoclonal antibodies, biosimilars, and recombinant proteins. The success of this partnership reinforces Mabion’s position as a world-class biologics CDMO, capable of handling the complex challenges of modern biopharmaceutical manufacturing. JAKUB KNUREK Marketing Specialist Mabion
RkJQdWJsaXNoZXIy MjY2OTA4MA==